Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 7/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | TXK | P42681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18316945 | 1.00 | PDE8B (0.40) | PDE8BITKCHEK2HRH3ALOX5AP | |
| SCHEMBL15575809 | 0.81 | PDE8B (0.46) | PDE8BCHEK2ALOX5APFEN1 | |
| SCHEMBL15575623 | 0.81 | PDE8B (0.46) | PDE8BCHEK2ALOX5APFEN1 | |
| SCHEMBL15575625 | 0.81 | PDE8B (0.46) | PDE8BCHEK2ALOX5APFEN1 | |
| SCHEMBL16987536 | 0.78 | ITK (0.42) | PDE8BITKKLK7 | |
| SCHEMBL16987532 | 0.78 | ITK (0.42) | PDE8BITKKLK7 | |
| SCHEMBL15615864 | 0.78 | ITK (0.42) | PDE8BITKKLK7 | |
| SCHEMBL18316791 | 0.77 | ITK (0.66) | ITKTXK | |
| SCHEMBL18316793 | 0.77 | ITK (0.66) | ITKTXK | |
| SCHEMBL10298674 | 0.72 | FPR3 (0.41) | PDE8BCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932329-B2 | Benzimidazole derivatives as RLK and ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | PRINCIPIA BIOPHARMA, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368908-A1 | BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS | ITK, BLK, LMTK2 | PDE8B 3017/4885ITK 1/4885CHEK2 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.